Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Latest advances in mHSPC from ASCO GU 2020

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.02.20
Views: 1126

Dr Eleni Efstathiou and Prof Axel Merseburger

Dr Eleni Efstathiou (MD Anderson Cancer Center, Houston, USA) and Prof Axel Merseburger (University Hospital Schleswig-Holstein, Lübeck, Germany) discuss the recent European approval of apalutamide for the treatment of metastatic hormone-sensitive prostate cancer at ASCO GU 2020 in San Francisco.

Prof Merseburger gives an overview of the TITAN trial and the results that supported the approval of apalutamide in this setting, including the evaluation of time to second progression (PFS2) in these patients - which was presented at this year’s meeting.

The panel discuss the clinical impact of this approval and how hormonal agents are prescribed in both Europe and North America, emphasising the need for improved education among healthcare professionals to use these therapies effectively.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Approval of apalutamide for the treatment of mHSPC
Clinical impact of apalutamide
Significance of PFS2
The use of hormonal agents in the US and EU
Safety profile of apalutamide


Related videos

follow us

Biosimilar Medicines Core Principles and Communication

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation